Voleon Capital Management LP Increases Stake in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Voleon Capital Management LP increased its stake in Ironwood Pharmaceuticals by 952.4%, acquiring an additional 787,901 shares, bringing its total ownership to 870,629 shares valued at approximately $1.28 million.
• Ironwood Pharmaceuticals reported an earnings per share (EPS) of $0.14 for the last quarter, significantly surpassing analysts' expectations of ($0.02), and generated $85.24 million in revenue.
• Wall Street Zen upgraded Ironwood Pharmaceuticals' stock rating from "hold" to "strong-buy," with an average target price set at $4.94.

Voleon Capital Management LP grew its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 952.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 870,629 shares of the biotechnology company's stock after purchasing an additional 787,901 shares during the quarter. Voleon Capital Management LP owned approximately 0.54% of Ironwood Pharmaceuticals worth $1,280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of IRWD. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth approximately $36,000. Simplicity Wealth LLC bought a new position in shares of Ironwood Pharmaceuticals in the first quarter worth approximately $45,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Ironwood Pharmaceuticals in the first quarter worth approximately $57,000. Y Intercept Hong Kong Ltd boosted its position in shares of Ironwood Pharmaceuticals by 162.6% during the first quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company's stock worth $58,000 after acquiring an additional 24,635 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $59,000.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $4.94.

Ironwood Pharmaceuticals Stock Up 5.6%

Ironwood Pharmaceuticals stock traded up $0.07 during mid-day trading on Friday, reaching $1.31. 816,432 shares of the company's stock traded hands, compared to its average volume of 1,224,465. The company has a market cap of $212.78 million, a price-to-earnings ratio of -26.19 and a beta of 0.32. The stock has a 50 day moving average of $0.98 and a two-hundred day moving average of $0.96. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The company had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.